Image L- R: Ian De Havilland, Founder of NADClinic and Erin Lee, Co-Founder & CEO, NADairX®
NADairX® is set to debut its new inhalable NAD platform at FIBO 2026 in Cologne, taking place from 16–19 April. The system delivers a 60 mg dose of NAD+ via pulmonary inhalation, designed to enable rapid absorption into the bloodstream and bypass digestive barriers that can limit oral supplementation.
Co-founded by wellness entrepreneur Erin Lee and longevity researcher Iain De Havilland, the platform was developed with support from NADclinic, which recognised the potential of pulmonary delivery to broaden access to NAD+ therapies and expand its longevity product portfolio.
The initial rollout will focus on B2B partners, including longevity clinics, wellness operators, recovery centres and fitness facilities. Pre-orders for industry partners open on 13 April 2026, ahead of the platform’s official unveiling at FIBO.
Speaking about the launch, Erin Lee said: “Our goal was to explore whether pulmonary delivery could offer a more accessible and scalable way for people to engage with NAD+therapies.”
Iain De Havilland added: “As interest in NAD+ therapies continues to grow, it’s important that we explore delivery methods that are practical, scalable, and biologically credible. Pulmonary delivery represents an exciting pathway that could help broaden access while complementing existing clinical approaches.”
